BBC 📈 Virtus LifeSci Biotech - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US26923G3011 • Health
BBC: Biotechnology, Clinical Trial Drugs, Medical Treatments
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. ‣ Company URL: http://www.virtus.com ‣ Domicile: United States
Additional Sources for BBC ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBC ETF Overview
| Market Cap in USD | 10m |
| Category | Health |
| TER | 0.79% |
| IPO / Inception | 2014-12-16 |
BBC ETF Ratings
| Growth 5y | -39.6% |
| Fundamental | - |
| Dividend | 6.0% |
| Rel. Strength Industry | -65.8 |
| Analysts | - |
| Fair Price Momentum | 20.96 USD |
| Fair Price DCF | - |
BBC Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 20.0% |
BBC Growth Ratios
| Growth Correlation 3m | -57.8% |
| Growth Correlation 12m | 23.5% |
| Growth Correlation 5y | -62.3% |
| CAGR 5y | -8.99% |
| CAGR/Mean DD 5y | -0.22 |
| Sharpe Ratio 12m | 0.13 |
| Alpha | -24.83 |
| Beta | 1.08 |
| Volatility | 47.04% |
| Current Volume | 1.2k |
| Average Volume 20d | 3.3k |
What is the price of BBC stocks?
As of December 22, 2024, the stock is trading at USD 24.33 with a total of 1,212 shares traded.
Over the past week, the price has changed by -2.89%, over one month by -7.02%, over three months by -16.65% and over the past year by +9.39%.
As of December 22, 2024, the stock is trading at USD 24.33 with a total of 1,212 shares traded.
Over the past week, the price has changed by -2.89%, over one month by -7.02%, over three months by -16.65% and over the past year by +9.39%.
Is Virtus LifeSci Biotech a good stock to buy?
Probably not. Based on ValueRay Analyses, Virtus LifeSci Biotech (NYSE ARCA:BBC) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -39.57 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBC as of December 2024 is 20.96. This means that BBC is currently overvalued and has a potential downside of -13.85%.
Probably not. Based on ValueRay Analyses, Virtus LifeSci Biotech (NYSE ARCA:BBC) is currently (December 2024) not a good stock to buy. It has a ValueRay Growth Rating of -39.57 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBC as of December 2024 is 20.96. This means that BBC is currently overvalued and has a potential downside of -13.85%.
Is BBC a buy, sell or hold?
Virtus LifeSci Biotech has no consensus analysts rating.
Virtus LifeSci Biotech has no consensus analysts rating.
What are the forecast for BBC stock price target?
According to ValueRays Forecast Model, BBC Virtus LifeSci Biotech will be worth about 23.4 in December 2025. The stock is currently trading at 24.33. This means that the stock has a potential downside of -3.95%.
According to ValueRays Forecast Model, BBC Virtus LifeSci Biotech will be worth about 23.4 in December 2025. The stock is currently trading at 24.33. This means that the stock has a potential downside of -3.95%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.4 | -3.9% |